Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mineralys Therapeutics (Nasdaq: MLYS) reported financial results for 2022, announcing a net loss of $29.8 million, up from $19.4 million in 2021. Cash and equivalents increased to $110.1 million following a successful IPO in February, yielding approximately $202 million in net proceeds. The pivotal clinical program for lorundrostat, targeting uncontrolled hypertension, is set to begin in H1 2023. Recent positive Phase 2 trial data supports this initiation, with topline results expected in 2024. Upcoming trials include a Phase 3 study in H2 2023 and a chronic kidney disease trial mid-2023.
- Successful IPO raised approximately $202 million for further development.
- Positive topline data from Target-HTN Phase 2 trial supports advancement of lorundrostat.
- Initiation of pivotal trials for lorundrostat planned for H1 2023.
- Net loss increased to $29.8 million for 2022, indicating rising financial pressures.
- R&D expenses rose significantly to $26.3 million in 2022, leading to concerns about cost management.
– Lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled hypertension, expected to begin in the first half of 2023 –
–IPO and Nasdaq listing completed in February 2023 with total net proceeds of approximately
– Conference call today at 4:30 p.m. ET –
RADNOR, Pa., March 15, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced financial results for the fourth quarter and full year ending December 31, 2022, and provided a corporate update.
“I am extremely proud of the Mineralys Therapeutics team as we continue to make tremendous progress advancing the clinical development of lorundrostat – our proprietary highly selective aldosterone synthase inhibitor designed to reduce aldosterone levels – for the treatment of hypertension. This is a critical milestone in our Company’s history, as we prepare to initiate the pivotal program to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled and resistant hypertension in the first half of 2023,” stated Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. “Uncontrolled and resistant hypertension continue to impact individual patient’s lives and the healthcare system at large. The closing of our IPO in February enables us to continue our efforts of developing a targeted treatment approach for hypertension with lorundrostat.”
Recent Corporate and Clinical Highlights
- Topline Data Target-HTN Phase 2 trial – In November 2022, the Company announced positive topline data from its Target-HTN trial, a Phase 2 proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN), which support advancing the development of lorundrostat into the planned pivotal clinical program.
- FDA End of Phase 2 Meeting – In November 2022, the Company held an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to review the positive results of the Target-HTN trial, and to discuss the plans for a pivotal program for lorundrostat in hypertension. Based on the Phase 2 results and feedback from the FDA, the Company intends to initiate the pivotal program in the first half of 2023.
- Presented Phase 2 Results at ACC.23/WCC – In March 2023, the Company presented positive data from the Target-HTN Phase 2 study that demonstrated clinically meaningful blood pressure reduction with once-daily dosing of lorundrostat at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC), including a pre-specified analysis of hypertensive subjects with a body mass index (BMI) ≥30 kg/m2 (obese) that showed lorundrostat demonstrated a statistically significant placebo-adjusted reduction in systolic blood pressure.
- Presented Phase 1 Results at ACC.23/WCC – In March 2023, the Company presented Phase 1 data from a first-in-human, safety, tolerability, pharmacokinetics, and pharmacodynamics study – conducted by Mitsubishi Tanabe Pharma – of single ascending dose and multiple ascending doses of lorundrostat that showed it was well-tolerated and had the predicted effect of suppressing aldosterone in a dose-dependent fashion without inhibiting cortisol.
- Completed an Initial Public Offering (IPO) – In February 2023, the Company completed an initial public offering of 13.8 million shares of common stock at a price of
$16.00 per share for net proceeds of approximately$202.0 million , after deducting underwriting discounts, commissions, and estimated offering-related expenses. - NASDAQ Listing – Listed the Company’s common stock on the Nasdaq Global Select Market under the ticker symbol “MLYS.”
Key Upcoming Milestones
- ADVANCE-HTN Phase 2 pivotal trial – In the first half of 2023, the Company plans to initiate the ADVANCE-HTN Phase 2 trial to evaluate the safety and efficacy of lorundrostat for the treatment of uHTN and rHTN, when used as an add-on therapy to standardized background treatment of two or more antihypertensive medications in up to approximately 300 adult subjects. The topline data from this trial is expected in the first half of 2024.
- Phase 3 pivotal trial – In the second half of 2023, the Company plans to initiate a randomized, double-blind, placebo-controlled Phase 3 trial to evaluate the safety and efficacy of lorundrostat for the treatment of uHTN and rHTN, when used as an add-on therapy to prescribed background treatment of two or more antihypertensive medications in up to approximately 1,000 adult subjects. The topline data from this trial is expected in mid-2025.
- CKD profiling trial – In mid-2023, the Company plans to initiate a randomized, double-blind, placebo-controlled Phase 2 trial to evaluate the safety and efficacy of lorundrostat for the treatment of uHTN and rHTN in a chronic kidney disease (CKD) population. Topline data from this trial expected in the first half of 2024.
- Open label extension trial for long-term safety exposure – In mid-2023, the Company plans to initiate an open label extension trial to obtain additional safety data - all subjects in the pivotal hypertension program, including the ADVANCE and Phase 3 trials will be given the opportunity to participate.
Fourth Quarter and Full-Year 2022 Financial Highlights
Research and Development (R&D) expenses were
General and Administrative (G&A) expenses were
Net loss was
Cash, cash equivalents, and marketable securities were
Conference Call
The Company’s management team will host a conference call at 4:30 p.m. ET on Wednesday, March 15, 2023. To access the call, please dial 1-877-704-4453 in the U.S. or 1-201-389-0920 outside the U.S., followed by the conference ID: 13736564. A live webcast of the conference call may be found here. A replay of the call will be available on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Hypertension
Having sustained, elevated blood pressure (or hypertension) increases the risk of heart disease, heart attack, and stroke, which are leading causes of death in the U.S. In 2020, more than 670,000 deaths in the U.S. included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an average annual economic burden of about
Less than 50 percent of hypertension patients achieve their blood pressure goal with currently available medications. Abnormally elevated aldosterone levels are a key factor in driving hypertension in approximately 25 percent of all hypertensive patients.
About Lorundrostat
Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro and an observed half-life of 10-12 hours. In a Phase 2, proof-of-concept study (Target-HTN) in uncontrolled and resistant hypertensive subjects, once-daily lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension, in both automated office blood pressure measurement and 24-hour ambulatory blood pressure monitoring. Adverse events observed were a modest increase in serum potassium, decrease in estimated glomerular filtration rate, urinary tract infection and hypertension with one serious adverse event possibly related to study drug being hyponatremia.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is initially developing for the treatment of patients with uncontrolled hypertension. Mineralys Therapeutics is based in Radnor, PA, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Forward-Looking Statements
Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the planned future clinical development of lorundrostat and the timing thereof; and expected timing of topline results from clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment, and completion of clinical trials and nonclinical studies; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval, and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; our ability to maintain undisrupted business operations due to the COVID-19 pandemic or any other pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
Mineralys Therapeutics, Inc.
Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
| Three Months Ended | Year Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 7,818 | $ | 6,616 | $ | 26,250 | $ | 16,308 | |||||||
| General and administrative | 2,190 | 467 | 5,229 | 2,417 | |||||||||||
| Total operating expenses | 10,008 | 7,083 | 31,479 | 18,725 | |||||||||||
| Loss from operations | (10,008 | ) | (7,083 | ) | (31,479 | ) | (18,725 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Interest income (expense), net | 935 | — | 1,676 | (27 | ) | ||||||||||
| Change in fair value of convertible notes | — | — | — | (657 | ) | ||||||||||
| Other income | — | — | 4 | 1 | |||||||||||
| Total other income (expense), net | 935 | — | 1,680 | (683 | ) | ||||||||||
| Net loss | $ | (9,073 | ) | $ | (7,083 | ) | $ | (29,799 | ) | $ | (19,408 | ) | |||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (1.74 | ) | $ | (1.40 | ) | $ | (5.77 | ) | $ | (3.89 | ) | |||
| Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted | 5,210,456 | 5,058,938 | 5,167,296 | 4,984,286 | |||||||||||
Mineralys Therapeutics, Inc.
Selected Financial Information
Condensed Consolidated Balance Sheet Data
(amounts in thousands)
(unaudited)
| December 31, | |||||||
| 2022 | 2021 | ||||||
| Cash and cash equivalents | $ | 87,701 | $ | 10,612 | |||
| Marketable securities | $ | 22,409 | $ | — | |||
| Total assets | $ | 114,442 | $ | 11,125 | |||
| Total liabilities | $ | 8,067 | $ | 5,054 | |||
| Total stockholders’ deficit | $ | (52,269 | ) | $ | (22,925 | ) | |
FAQ
What were the financial results for Mineralys Therapeutics in 2022?
When is the pivotal clinical program for lorundrostat expected to begin?
What is the significance of the IPO completed by Mineralys Therapeutics?
What are the upcoming milestones for Mineralys Therapeutics?
